We expect that such analyses will indicate IGF2BP1 and IGF2BP3 as useful biomarkers for evaluating tumor aggressiveness and will reveal avenues to pursue analyzing their suitability for targeted therapy. The gene discussed is IGF2BP3; the disease is neoplasm.